Prostatype Genomics AB (FRA:PGO0) Other Stockholders Equity: €-19.22 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PGO0 Prostatype Genomics AB FRA:PGO0
14 GF Score
Price €0.01
! 6 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Other Stockholders Equity?

Prostatype Genomics AB FRA:PGO0 -2.04% 14 Other Stockholders Equity is €-19.22 Mil as of Jun. 2026. GuruFocus rates FRA:PGO0 with a GF Score™ of 14/100. The stock has 6 warning signs investors should review.

Prostatype Genomics AB's Other Stockholders Equity for the quarter that ended in Jun. 2026 was €-19.22 Mil.

Prostatype Genomics AB's quarterly Other Stockholders Equity declined from Jun. 2025 (€-15.59 Mil) to Dec. 2025 (€-17.57 Mil) and declined from Dec. 2025 (€-17.57 Mil) to Jun. 2026 (€-19.22 Mil).

Prostatype Genomics AB's annual Other Stockholders Equity increased from Dec. 2023 (€-14.27 Mil) to Dec. 2024 (€-13.12 Mil) but then declined from Dec. 2024 (€-13.12 Mil) to Dec. 2025 (€-17.57 Mil).

Prostatype Genomics AB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Other Stockholders Equity Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 1.81 -11.33 -14.27 -13.12 -17.57

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.92 -13.12 -15.59 -17.57 -19.22
FRA:PGO0
14GF Score
Prostatype Genomics AB FRA:PGO0
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-19.22 Mil mean?
Prostatype Genomics AB (FRA:PGO0) has a Other Stockholders Equity of €-19.22 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Other Stockholders Equity too high?
Prostatype Genomics AB's current Other Stockholders Equity is €-19.22 Mil. Overall, Prostatype Genomics AB has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Other Stockholders Equity compare to TMO and DHR?
Prostatype Genomics AB's Other Stockholders Equity of €-19.22 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Other Stockholders Equity is €-19.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Prostatype Genomics AB (FRA:PGO0) has a current Other Stockholders Equity of €-19.22 Mil. The current Other Stockholders Equity is €-19.22 Mil. Prostatype Genomics AB's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Prostatype Genomics AB (FRA:PGO0), the current Other Stockholders Equity is €-19.22 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prostatype Genomics AB Business Description

Other Exchanges PROGEN:Sweden
Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
14GF Score

Get the complete analysis for FRA:PGO0

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price